Beta
407585

Detection of occult hepatitis C virus infection among Egyptian patients with hepatocellular carcinoma who achieved sustained virologic response to direct-acting antiviral therapy

Article

Last updated: 01 Feb 2025

Subjects

-

Tags

-

Abstract

Background
Occult hepatitis C virus infection (OCI) is defined as the presence of hepatitis C virus (HCV) RNA in nonserum reservoirs without any detectable HCV-RNA in serum by standard assays. The association between OCI and hepatocellular carcinoma (HCC) is controversial. Direct-acting antiviral (DAA) therapy effectively controls HCV infection and proves sustained virological response (SVR). However, HCC after DAA therapy is debatable.
Objective
In this study, we tried to detect OCI in HCC Egyptian patients who achieved SVR post-DAA therapy for possible correlation and prediction for HCC.
Patients and methods
A cross–sectional study included seventy HCC Egyptian patients who achieved SVR post sofosbuvir/daclatasvir (SOF/DACLA) +/–ribavirin therapy. HCV-RNA was detected in peripheral blood mononuclear cells (PBMCs) by RT-PCR. Immune transmission electron microscopy (TEM) was done to study OCI in PBMCs using specific anti-HCV antibodies.
Results and conclusion
TEM examination revealed positive OCI in PBMCs of all patients (70/70) with 3 stages of grading reflecting viral particle load in PBMCs, with 68.6% of the patients having a marked OCI grade, while PCR only detected 5.7% (4/70) of OCI. Nearly 67.1% of the cases received dual anti-HCV therapy (sofosbuvir/daclatasvir). Ribavirin-inclusive DAA treatment shows a higher grade of OCI (P=0.02). The average duration from SVR to HCC development was 29.8±13.4 months. In conclusion, DAA drugs effectively eliminate HCV in serum, but OCI is still considered a risk for developing HCC, recommending a re-definition for SVR through detecting HCV-RNA in serum, PBMCs, and TEM studies. Our study is the first to provide electron microscopy as a sensitive tool for OCI detection with established superiority over the PCR technique.

DOI

10.21608/epj.2025.407585

Keywords

Direct-acting antiviral drugs, Hepatocellular carcinoma, immune electron microscopy, occult hepatitis C infection

Authors

First Name

Fatma

Last Name

Kassem

MiddleName

E.M.A.

Affiliation

Department of Electron Microscopy, Theodore Bilharz Research Institute, Giza, Egypt

Email

-

City

-

Orcid

-

First Name

Emtethal

Last Name

El-Kholy

MiddleName

E.

Affiliation

Department of Clinical Pathology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt

Email

-

City

-

Orcid

-

First Name

Amira

Last Name

Mohamed

MiddleName

H.

Affiliation

Department of Electron Microscopy, Theodore Bilharz Research Institute, Giza, Egypt

Email

-

City

-

Orcid

-

First Name

Abeer

Last Name

Abdul-Mohaymen

MiddleName

M.

Affiliation

Department of Clinical Pathology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt

Email

-

City

-

Orcid

-

First Name

Asmaa

Last Name

Gomaa

MiddleName

I.

Affiliation

Department of Tropical Medicine, National Liver Institute, Menoufia University, Menoufia, Egypt

Email

-

City

-

Orcid

-

First Name

Ayat

Last Name

Hassan

MiddleName

S.M.

Affiliation

Department of Electron Microscopy, Theodore Bilharz Research Institute, Giza, Egypt

Email

-

City

-

Orcid

-

Volume

24

Article Issue

2

Related Issue

53352

Issue Date

2025-04-01

Receive Date

2025-01-28

Publish Date

2025-04-01

Page Start

171

Page End

180

Print ISSN

1687-4315

Online ISSN

2090-9853

Link

https://epj.journals.ekb.eg/article_407585.html

Detail API

http://journals.ekb.eg?_action=service&article_code=407585

Order

3

Type

Original Article

Type Code

3,349

Publication Type

Journal

Publication Title

Egyptian Pharmaceutical Journal

Publication Link

https://epj.journals.ekb.eg/

MainTitle

Detection of occult hepatitis C virus infection among Egyptian patients with hepatocellular carcinoma who achieved sustained virologic response to direct-acting antiviral therapy

Details

Type

Article

Created At

01 Feb 2025